Genmab — Maj 2021
-
Tirsdagens aktier: Inflationsfrygt tog humøret - Lundbeck til tops. https://www.proinvestor.com/investornyt/675004/tirsdagens-aktier-inflationsfrygt-tog-humoret-lundbeck-til-tops
-
@Sukkeralf any thoughts on that Immatics news? (from looking at their pipeline this does not seem like one of the
Genmab bispecifics?) -
US Biotech viser overraskende styrke i negativt marked
https://www.proinvestor.com/investornyt/675010/us-biotech-viser-overraskende-styrke-i-negativt-marked -
God morgen.
-
God morgen
-
Video: Tæt på Scandion Oncology, Ascelia Pharma & Hansa.:
https://www.proinvestor.com/index.php?p=debat_1&postid=93476 -
Spørgsmål til Q&A på mandag er mere end velkommen. Jeg har kun 5 stk´s inde nu.
-
I assume this is MIM-8 / Novo Nordisk ? Orphan Designation
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=814121 -
EHA Late breaking Dara abstract - SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY - https://library.ehaweb.org/eha/2020/eha25th/303396/efstathios.kastritis.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.html?f=listing%3D1*browseby%3D4*sortby%3D2*media%3D3*ce_id%3D1766*search%3Ddaratumumab*marker%3D794
-
EHA poster SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325259/rogier.mous.subcutaneous.epcoritamab.in.patients.with.relapsed.refractory.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab
-
DARATUMUMAB MAINTENANCE VS OBSERVATION, finaly - Conclusion
CASSIOPEIA part 2 interim analysis showed a significantly longer PFS with daratumumab maintenance vs OBS in transplant-eligible patients with NDMM. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324588/philippe.moreau.daratumumab.maintenance.vs.observation.in.patients.with.newly.html?f=listing%3D1*browseby%3D8*sortby%3D2*media%3D3*ce_id%3D2035*label%3D21988*ot_id%3D25572*search%3Ddaratumumab*marker%3D1285 -
If you only look at patients receiving optimal dose of Epcoritamab (48 mg), isn’t the Epcoritamab data better then?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind